Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach
The Prostate · 2025
DOI: 10.1002/pros.24895 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Changhui Xue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Drug Resistance, Neoplasm, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This study is supported by NIH/NCI grants 5R01CA149253 and 5R01CA207377 to D.Z.Q..
Abstract (Originalsprache)
Background
Anti‐androgen or castration therapies are the mainstay treatment for metastatic prostate cancers (PCa). Although effective at first, androgen‐dependent PCa (ADPC) universally develops therapy resistance, thereby evolving into an incurable disease called castration‐resistant PCa (CRPC). Currently, mechanisms underlying the emergence of CRPC from ADPC are largely unclear.
Methods
We used single‐cell RNA‐sequencing (scRNA‐Seq) to determine the transcription heterogeneity of a therapy‐naïve ADPC cell line—LNCaP and how it responded to the anti‐androgen drug, enzalutamide. Based on the results, we used single‐cell/colony‐based cloning to isolate a pre‐enzalutamide cell subset, displaying low and/or no expression of androgen receptor (AR low/− ).
Results
We found that most LNCaP cells expressed enzalutamide‐target androgen receptor (AR+), while a small subpopulation (~10%) expressed low or no AR (AR low/− ). Gene set enrichment analysis (GSEA) revealed that AR + and AR low/− cells were enriched with significantly different gene expressions and signaling pathways. Unexpectedly, AR low/− cells displayed robust transcriptional response, including upregulations of genes and pathways involved in clinical CRPC. Next, we isolated AR low/− and AR + cells from enzalutamide‐naïve LNCaP cells and functionally confirmed the enzalutamide‐resistant phenotype of AR low/− cells in vitro and in xenograft models in vivo. Through xenograft‐based single‐nucleus RNA‐Seq, we further found that the AR low/− cells were selected, while the AR + cells were de‐selected in vivo by enzalutamide. Also, we found that the selection and expansion of AR low/− clone were recapitulated in another enzalutamide‐resistant cell model.
Conclusion
In summary, our single‐cell‐based sequencing and functional tests suggest a clonal selection and expansion model of enzalutamide resistance, in which the pretreatment AR‐low subpopulation is selected and expanded to confer treatment resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Hyun-Kyung Ko, David Z Qian
Förderung
- NCI NIH HHS
- This study is supported by NIH/NCI grants 5R01CA149253 and 5R01CA207377 to D.Z.Q.
Zitieren
APA
Xue, C., Ko, H. K., Shi, K., Pittsenbarger, J., Vu Dao, L., Shi, K., Libmann, M., Geng, H., & Qian, D. Z. (2025). Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach. The Prostate. https://doi.org/10.1002/pros.24895
Vancouver
Xue C, Ko HK, Shi K, Pittsenbarger J, Vu Dao L, Shi K, et al. Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach. The Prostate. 2025. doi:10.1002/pros.24895
BibTeX
@article{Xue2025,
author = {Xue, Changhui and Ko, Hyun-Kyung and Shi, Kasen and Pittsenbarger, Janet and Vu Dao, Lucien and Shi, Kaiyo and Libmann, Maximilian and Geng, Hao and Qian, David Z},
title = {Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24895}
}
EUVIMED